Merck & Co., Inc. (MRK) Weekday Company Research
Source: Financial Modeling Prep, as of 2026-07-16T10:10:12+00:00.
Company Overview
Merck & Co., Inc. is a global healthcare company operating through Pharmaceuticals and Animal Health. The Pharmaceutical segment includes products across oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, diabetes, and preventive vaccines. The Animal Health segment develops and markets veterinary medications, vaccines, health management solutions, and digital products for identification, traceability, and monitoring.
The company serves drug wholesalers, pharmacies, hospitals, government agencies, managed healthcare organizations, physicians and distributors, veterinarians, and livestock producers. Supplied company information also notes strategic collaborations with AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc.
Key Supplied Financial Snapshot
- Share price: $123.60
- Market capitalization: $305.27 billion
- Revenue: $64.93 billion
- Net income: $18.25 billion
- Operating income: $23.49 billion
- Free cash flow: $12.36 billion
- Cash: $14.57 billion
- Debt: $50.53 billion
- Equity: $52.61 billion
- Quality score: 75
Profitability and Cash Generation
Merck’s supplied profitability profile is strong. The company reported a net margin of 28.12% and an operating margin of 36.17%, supported by operating income of $23.49 billion on revenue of $64.93 billion. Free cash flow was positive at $12.36 billion, equal to a free cash flow margin of 19.04%.
These figures suggest a business with meaningful earnings power and cash generation in the supplied period. However, margins in pharmaceuticals can be affected by product mix, patent cycles, regulatory outcomes, litigation, reimbursement pressure, and research and development productivity. The supplied dataset does not include product-level revenue, pipeline details, patent-expiration schedules, or forward guidance.
Balance Sheet Considerations
Merck reported $14.57 billion in cash and $50.53 billion in debt, with equity of $52.61 billion. The supplied debt-to-equity ratio is 0.96. This indicates leverage is significant relative to equity, though the dataset does not include debt maturities, interest expense, credit ratings, covenant details, or refinancing terms.
The company’s positive free cash flow is a constructive factor, but the absolute debt level remains an important risk factor to monitor, especially if earnings, cash conversion, or financing conditions deteriorate.
Quality Score Interpretation
The supplied quality score is 75. This is a useful summary indicator, but the methodology behind the score is not included in the supplied facts. Therefore, the score should be treated as a screening input rather than a complete investment conclusion.
Data Limitations
This report uses only the structured facts supplied by Financial Modeling Prep. Several important investment inputs are Data Unavailable, including valuation multiples, dividend yield, dividend history, earnings guidance, analyst estimates, product concentration, pipeline data, clinical trial outcomes, patent cliffs, litigation exposure, regulatory actions, segment-level profitability, debt maturity schedule, interest expense, and historical trend data.
Because these items are not available in the supplied evidence, this research note cannot assess whether MRK is undervalued, fairly valued, or overvalued on a comprehensive basis.
Balanced Research View
On the positive side, Merck shows substantial scale, high reported margins, positive free cash flow, and a quality score of 75 in the supplied dataset. Its healthcare focus and diversified customer base may support business resilience, though this cannot be guaranteed from the supplied facts alone.
On the risk side, debt is material relative to equity, and the supplied data does not provide enough evidence to evaluate future growth, patent risk, pipeline durability, regulatory exposure, or valuation attractiveness. Investors should avoid relying on one-period profitability and cash flow figures without additional due diligence.
Educational Disclosure
This report is provided for educational and research purposes only and is not financial advice, investment advice, or a recommendation to buy, sell, or hold any security. Investment outcomes are uncertain, and downside risk is possible. Readers should conduct independent research and consult a qualified financial professional before making investment decisions.